Abstract 3639: EGCG-gold nanoparticles exhibit greater anti-tumor activity over conventional gold nanoparticles or EGCG due to potential synergistic interactions

Abstract

Epigallocatechin gallate (EGCG) possesses significant anti-tumor activity and binds to laminin receptor over-expressed on cancer cells with high affinity. However, the use of EGCG in therapeutics is limited due to its poor bioavailability and limited stability. Gold nanoparticles (GNPs) serve as excellent drug carriers and protect the conjugated drug from enzymatic metabolization. Here, we investigated if EGCG-formulated GNPs (E-GNPs) would demonstrate superior anti-cancer activity compared to EGCG or conventionally-synthesized citrate-GNPs (C-GNPs) due to their synergistic interactions. Cell viability studies showed greater growth inhibition by E-GNPs, compared to EGCG, or C-GNPs. Cellular uptake studies revealed that, unlike C-GNPs, E-GNPs were taken-up more efficiently by cancerous cells than noncancerous cells. Furthermore, data showed that E-GNPs induced more apoptosis in cancer cells, compared to EGCG, and C-GNPs. From the mechanistic standpoint, we observed that E-GNPs inhibited the nuclear translocation and transcriptional activity of NF-κB with greater potency than EGCG, whereas C-GNPs were only minimally effective. Altogether, our data suggest that E-GNPs can serve as effective anti-cancer agents. Citation Format: Suhash Reddy Chavva, Sachin Kumar Deshmukh, Rajashekhar Kanchanapally, Nikhil Tyagi, Jason W. Coym, Ajay P. Singh, Seema Singh. EGCG-gold nanoparticles exhibit greater anti-tumor activity over conventional gold nanoparticles or EGCG due to potential synergistic interactions [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3639.